| I am excited to share important news about Mary Crowley Cancer Research's next chapter. Mary Crowley Cancer Research entered into an Asset Purchase Agreement with Sarah Cannon Research Institute on January 2, 2025. Your steadfast support has been instrumental in advancing our mission of providing innovative treatment options for cancer patients through clinical trials. We are deeply grateful for your generosity and partnership, which have helped bring hope and healing to so many. Together, we remain committed to the principles that have guided us since our founding: compassion for patients, dedication to innovation, and an unwavering commitment to finding new and effective treatments for cancer. As we move forward, I assure you that the Mary Crowley Cancer Research Foundation will remain in operation. The Foundation will continue to play a vital role in supporting groundbreaking research efforts and assisting patients undergoing treatment through clinical trials. Thank you again for your support. Your contributions have been a cornerstone of our success and will continue to make a difference in the lives of patients and their families as we embark on this exciting new phase. If you have any questions or would like further information, please do not hesitate to reach out to me [email protected]. With gratitude,
Jennifer Fox CEO of Mary Crowley Cancer Research | 